Crenezumab, an anti-amyloid β (Abeta) antibody which Genentech in-licensed from AC Immune SA, failed to reach the primary endpoint of two phase II studies in Alzheimer's disease, but the drug has demonstrated tantalizing signs of efficacy in patients at the milder end of the Alzheimer's spectrum.
Johnson & Johnson's hepatitis C virus (HCV) drug Olysio (simeprevir) reached blockbuster status during the second quarter, clocking about $1.2 billion in sales for the first six months of the year.
Board disagreements have delayed the formal completion of the EMA's new policy on access to clinical trial data. The London-based regulatory agency disclosed late Wednesday that it was unable to agree on final wording for the new policy, which had been due to take effect Oct. 1.
DUBLIN – UK investors were unmoved Tuesday by Abbvie Inc's improved cash-and-shares indicative offer for Shire plc, which values the specialty pharma firm at £30.1 billion (US$51.3 billion), or at £51.15 per share.
Nicox SA is paying $65 million up front and could pay up to $55 million more in a cash-free, stock-based acquisition of Aciex Therapeutics Inc. that gives it a near-term shot at a product approval.
Shares in Mologen AG rose 13 percent Monday on interim survival data indicating that a small subgroup of patients with metastatic colorectal cancer experienced lengthy – and ongoing – progression-free survival (PFS) with cancer immunotherapy MGN1703.
Shareholders in Nordic Nanovector AS voted Friday to approve an NOK250 million (US$40.6 million) private placement and to raise the offering by a further NOK50 million, evidence that Bayer AG's recently closed $2.9 billion buyout of radiopharmaceutical developer Algeta ASA has had a positive impact on investor sentiment in Norway.
As is so often the case with gastrointestinal disease, Index Pharmaceuticals AB obtained phase III results with its topical ulcerative colitis drug Kappaproct that were neither black nor white but a distinct shade of gray.
Shares in Dublin-based Shire plc rose 12 percent Friday morning as the company went public on its rejection of a £27 billion (US$46 billion) cash-and-shares takeover bid from Abbvie Inc.
Shares in Cellectis SA surged more than 50 percent during trading in Paris Wednesday after Pfizer Inc. unveiled a strategic collaboration in cancer based on the French firm's allogeneic chimeric antigen receptor T-cell (CAR T-cell) platform, which will involve an initial outlay of about $112 million, as well as research funding, milestones that could reach as much as $2.775 billion in total, and tiered royalties on any products that reach the market.
